Haleos Labs to Transfer Unclaimed Shares to IEPF by Nov 5, 2026
Haleos Labs Limited is transferring unclaimed shares from FY 2018-19 to the IEPF suspense account. Shareholders must claim unpaid dividends by November 5, 2026, to prevent share transfer. Public notices have been issued, and details are on the company website.
This is a regulatory compliance action concerning unclaimed shares and dividends, which typically has a minimal direct impact on the company's operations or financial performance. The impact is limited to shareholders who have not claimed their dividends or shares.
The announcement is a routine regulatory filing regarding the transfer of unclaimed shares and dividends to the IEPF, which is a standard procedure under the Companies Act. It does not inherently indicate positive or negative performance of the company.
Haleos Labs Limited has communicated a notice to its shareholders regarding the compulsory transfer of shares pertaining to FY 2018-19 to the Investor Education and Protection Fund (IEPF) suspense account. This action is in accordance with the Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016.
Separate communications have been dispatched via speed post to individual shareholders whose shares are liable for transfer. Additionally, a public notice has been published in "Business Standards" (English) and "Telugu Prabha" (Telugu). The company has also made unclaimed dividend details available on its website, www.haleoslabs.com.
Shareholders who have unpaid or unclaimed dividends for the financial year 2018-19 onwards are requested to claim their dividends by submitting an application to the company's Registrar and Transfer Agents, Aarthi Consultants Pvt. Ltd., on or before November 5, 2026. Failure to do so will result in the transfer of their shares, in both physical and electronic forms, to the IEPF suspense account. The company has also noted that claims for unclaimed dividends and shares can be made from the IEPF Authority after following the prescribed procedure.
What to do with a filing like this
HALEOS LABS LIMITED filed this with the NSE as a statutory disclosure, categorised under other regulatory filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by HALEOS LABS LIMITED. Read the original for the full detail.